Key Highlights
- Tommy Leggett appointed as new CFO of Stoke Therapeutics, bringing over 20 years of biotech executive experience.
- Succeeds Stephen Tulipano, who played a crucial role in Stoke’s IPO and recent financings.
- Focus on advancing STK-001 into a registrational study and expanding the pipeline of disease-modifying medicines.
Source: Business Wire
Notable Quotes
- “We welcome Mr. Leggett to Stoke and look forward to working with him to build on this strong foundation as Stoke enters a new phase of growth. I want to thank Mr. Tulipano for his contributions to Stoke over the past five years. He has led multiple financings, including Stoke’s highly successful Initial Public Offering in 2019,” – Edward M. Kaye, M.D., Chief Executive Officer at Stoke Therapeutics
- “I look forward to working with the Stoke leadership team and share their deep commitment to Stoke’s mission of delivering novel new medicines to people living with severe diseases like Dravet syndrome,” – Tommy Leggett, Chief Financial Officer (CFO) at Stoke Therapeutics, Inc
SoHC's Take
The appointment of Tommy Leggett as CFO represents a strategic move for Stoke Therapeutics at a crucial juncture in its evolution. With a proven track record in financial strategy and leadership in the biotech sector, Mr. Leggett is well-positioned to steer Stoke through its next phase of growth and clinical advancements. His extensive experience, particularly in leading significant financial initiatives and IPOs, aligns perfectly with Stoke’s ambitions to further develop and commercialize their pioneering RNA-based medicines. This transition also reflects Stoke’s commitment to maintaining a robust leadership structure, capable of navigating the challenges of the highly competitive biotech industry.
